Lioresal (baclofen) is a muscle relaxant used to treat muscle spasms caused by multiple sclerosis and spinal cord injuries. It has general central nervous system-depressant actions mainly at the spinal cord level and the upper motor neurons. Lioresal (baclofen) inhibits the transmission of synaptic reflexes.

Lioresal is taken by mouth in 5 mg doses three times a day. Dosage may be increased by daily 15 mg increments every three days up to a maximum dosage of 80 mg per day.

The most common side effects are confusion, dizziness or light-headedness, drowsiness, nausea, and muscle weakness. All common side effects may disappear once the body has adjusted to the treatment. After stopping the treatment, however, some serious side effects that may occur include convulsions, hallucinations, increase in muscle spasms, cramping or tightness, and emotional changes.

Generics available on the U.S. market for baclofen as an alternative to the brand-name Lioresal.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.


#ECTRIMS2019 – Mollii Suit Can Ease Muscle Stiffness and Improve Movement, Reports State

Mollii, an electrostimulation suit, can help reduce muscle stiffness, or spasticity, and its associated pain, as well as improve muscle activation in people with multiple sclerosis (MS), cerebral palsy, stroke, and other neurological injuries, according to Inerventions, the Swedish company that developed and markets it. With a few hours of weekly treatment people report better control […]

MS News that Caught My Eye Last Week: Dark Rimmed Lesions, Sativex in the UK, NHS Care Toolkit for Neurological Diseases, Wahls Diet

Dark Rimmed Brain Lesions May Be Signal of Aggressive Disease, NIH Study Says Researchers in this study found that specific brain lesions, notable for their dark rims, may indicate that a patient’s multiple sclerosis is likely to progress quickly. They suggest that early detection of these lesions can help doctors to decide to begin aggressive […]

NICE and NHS England Oppose Sativex to Treat Spasticity in MS, Urge More Studies of Medical Cannabis

A draft guidance issued by the National Institute for Health and Care Excellence (NICE), a U.K. advisory board, and a review by England’s National Health Service (NHS) call for more research into medical cannabis for multiple sclerosis and other conditions. NICE also recommended against prescribing Sativex as a treatment for spasticity (muscle stiffness) in people with  MS for reasons related […]

My Pain Is Real — Don’t Deny Me Relief

I am quite outspoken. I have no problem voicing my opinion or needs — or so I thought. An exchange this morning left me speechless. While my head was swimming with semi-intelligible responses, I was rendered mute. Let me just say that I have been on pain medication for a long while. I receive my […]

PathMaker Neurosystems Wins France’s Top Prize for Innovation for Spasticity Treatment

The developer of an innovative, first-in-class, noninvasive device for the treatment of spasticity in multiple sclerosis (MS) and other conditions has won the 2019 CCI France International Trophy for Innovation. PathMaker Neurosystems was selected from a list of eight finalist companies, which were distinguished among 150 nominees from 40 countries and across all technology sectors, […]

Less-frequent Dosing with Arbaclofen ER Tablets Decreases Spasticity As Well As Standard Baclofen, MS Trial Data Show

Arbaclofen extended-release (ER) tablets taken twice a day can effectively reduce spasticity (muscle stiffness) in patients with multiple sclerosis (MS) with similar potency to that of standard and more-frequently-dosed baclofen (brand name Lioresal), Phase 3 clinical trials show. Latest trial data were presented in two posters during the 33rd Annual Meeting of the Consortium of Multiple Sclerosis Centers […]

FDA Approves Botox to Treat Upper Limb Spasticity in Children Aged 2 to 17

The U.S. Food and Drug Administration (FDA) has approved the use of Botox (onabotulinumtoxinA), marketed by Allergan, for the treatment of children ages 2 to 17 with upper limb muscle stiffness or spasticity, a common symptom in children with multiple sclerosis (MS). The agency is still reviewing the use of Botox for treating lower limb spasticity […]

Move It or Lose It: Movement Is Crucial to Well-being with MS

A well-known mantra exists in the multiple sclerosis (MS) community. I first heard it after my diagnosis and have since adopted it as my own. “Move it or lose it.” Movement is essential for everyone’s health and well-being. For those of us with multiple sclerosis, it is imperative. Regular activity will help to strengthen the […]

MS News that Caught My Eye Last Week: A Cure for MS?, MS App, Robot for Balance, Botox for Spasticity

All of the stories in this week’s column come from the recently held Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) forum, held Feb. 28 to March 2 in Dallas, Texas. #ACTRIMS2019 – Forum Leaders Discuss: ‘Will There Be a Cure for MS?’ A reporter for MS News Today asked this question, but the answers […]